Increase of the Expression of Receptors of Steroid Hormones in Patients with a Partial Androgen Deficiency of Aging Men (PADAM)
Abstract
Objectives: To study the disruption of the normal development cycle of cells with androgen receptors by partial androgen deficiency of aging men (PADAM).
Materials and Methods: In the current study, 15 patients were held under observation (5 with prostate cancer, 5 with bladder cancer and 5 with rectal cancer).
Results: The levels of testosterone in the tissues of the peritumorous zone of the prostate as well as in the tumorous tissue in patients with cancer of the prostate, bladder and rectum were higher than analogous indices in the blood serum. The indices of the histochemical score of androgen (AR) in the peritumorous zone among patients with prostate cancer were higher than the analogous indices of the control group; Upon research of the peritumorous zone among patients observed groups, expressions of ER, PR, bcl-2, Ki67 and p53 were detected.
Conclusions: The results of this study suggest the conclusion that production of testosterone by a whole set of tumors and tissues of the peritumorous zone, which is accompanied by increased proliferative activity and disturbance of the regulation of the cell cycle, is caused by PADAM. The given changes are directed at compensating for testicular deficiency.
References
1. Napalkov NP. Common oncology. Leningrad: Medicine,1989.
2. Bremner WJ, Vitietto MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. Clin Endocrin Metab 1983; 56:1278-81.
3. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex-hormone levels in middle-aged men: Results of the Massachusetts male aging study. Clin Endocrinol 1991; 73:1016-25.
4. Vermeulen A, Kaufman JM. Androgens and cardiovascular disease in men and women. The Aging Male 1998; 1:35-50.
5. Pechersky AV, Semiglazov VF, Mazurov VI, Karpischenko Al, Mikhailichenko VV, Udintsev AV, Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, estradiol and prostate volume. Intern J Androl 2002; 25: 119-25.
6. Pechersky AV, Semiglazov VF, Loran OB, et al. Changes in the level of cytokines among patients with prostate cancer after orchiectomy. Terra Medica, in its special thematic edition "Laboratory Diagnostics" 2003; 2: 26-30.
7. Bershtein LM. Hormonal carcinogenesis. St. Petersburg: Nauka, 2000.
8. Fernandez E, La Vecchia C, D'Avanzo B, Franceschi S, Parazinni F, Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer. Br J Cancer 1996;73:1431-5.
9. Lopatkin NA. Guide to urology. Moscow: Medicine, 1998: 3.
10. Lavin N. Endocrinology. Moscow: Practica,1999.
11. Loran OB, SegakI AS, Supryaga OM. Andriol in the treatment secretion infertility and climacteric syndrome in men. Urol Nephrol 1999; 3: 41-4.
12. Morales A, Bain J, Ruijs A. et al. Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Intern J Impot Res 1996;8:95-7.
13. Jonat W, Maass H, Stegner HE. Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res 1986; 46: 4296-8.
14. Glantz SA. Primer of biostatistics. Moscow: Practica, 1999.
15. Kettyle WM, Arky RA. Endocrine pathophysiology. Moscow: Binom Publishers, 2001.
16. Farber E. Cell proliferation as a major risk factor for cancer: a concept of doubtful validity. Cancer Res 1995; 55: 3759-62.
17. Sporn MB. The war on cancer. Lancet 1996; 347: 1377-81.
18. Russo J, Russo IH. Differentiation and breast cancer. Medicina (B. Aires) 1997; 57:81-91.
19. Vasilyev Yu. M. Social behavior of normal cells and antisocial behavior of tumorous cells. Soros Educational J 1997; 4:17-22.
20. Burrows H, Horning E. Oestrogens and neoplasia. Springfield, Illinois: Charles C. Thomas Publ, 1952. p. 189.
21. Zazerov VG, Severin ES. Molecular mechanisms of oncogenesis of the prostate. Vestnik of the Russian Academy of Medical Sciences 1998; 5: 29-35.
22. Neveu PJ, Le Moal M. Physiological basis for neuroimmunomodulation. Fundam Clin Pharmacol 1990;4: 281-305.
23. Besedovsky HO, Del Rey A. Immune-neuroendocrine interactions: facts and hypotheses. Endocrine Rev 1996;17:64-102.
24. Bershtein LM. Extragonadal Estrogen Production (role in physiology and pathology). St. Petersburg: Nauka, 1998.
25. Borkovwski A, Dosogne M, Declerq P, Muquardt C, Machin D. Estrogen oestradiol conversion by blood mononuclear cells in normal subjects and in patients with mammary and non-mammary carcinomas. Cancer Res 1978; 38: 2174-9.
26. Milewich L, Whisenant MG, Sawyer MK. Androstenedione metabolism by human lymphocytes. J Steroid Biochem 1982; 16:81-5.
27. Coddington CC, Letterie GS, Klein TA, Winkee CA. Androgen metabolism by human peritoneal macrophages. Steroids 1988;51:143-61.
28. Frisch RE, Canick JA, Tulchinsky D. Human fatty marrow aromatizes androgen to estrogen. J Clin Endocrinol Metabol 1980;51:394-6.
29. Lea CK, Ebrahim H, Tennant S, Flanagan AM. Aromatase cytochrome P450 transcripts are detected in fractured human bone but not in normal skeletal tissue, Bone 1997;21:433-40.
30. Mor G, Yue W, Santen RJ, et al. Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem and Mol Biol 1998;67: 403-11.
31. Weigent DA, Blalock JE. Interaction between neuroendocrine and immune systems: common hormones and receptors. Immunol Rev 1987; 100: 79-108.
32. Korneva EA, Shkhinek EK. Hormones and the Immune System. Leningrad: Nauka, 1988,
33. Pankov A. Yu. Prolactin. Large Medical Encyclopedia. Moscow: Sovetskaya Aencyclopedya, 1983; 21: 134.
34. Lueprasitsakul P, Longcope C. Aromatase activity of human adipose tissue stromal cells: effects of thyroid hormones and progestogens. Proc Soc Exp Biol and Med 1990; 194:337-41.
35. Jakob F, Homann D, Seufert J, Schneider D, Kohrle J. Expression and regulation of aromatase cytochrome P450 in THP1 human myeloid leukemia cells. Molec and Cell Endocrinol 1995; 110: 27-33.
36. Shozu M, Takayama K, Zhao Y, Simpson ER. Hormonally controlled alternative promoters regulate aromatase expression in human THP-1 cells. Proc 4th Intern Aromatase Conf. Tahoe City, California, 1996: A-15.
37. Mendelson CR, Simpson ER. Regulation of estrogen biosynthesis by human adipose cells in vitro. Molec and Cell Endocrinol 1987; 52: 169-76.
38. Ryde CM, Nicholls JE, Dowsett M. Steroid and growth factor modulation of aromatase activity in MCF7 and T 47D breast carcinoma cell lines. Cancer Res 1992;52: 1411-5.
39. Naz RK. Prostate: basic and clinical aspects. New York: CRC Press, 1997. p. 337.
40. Tareeva IE. Nephrology. Moscow: Medicine, 1995;1.
41. Franklin RB, Costello LC. Prolactin directly stimulates citrate production and mitochondrial aspartate aminotransferase of prostate epithelial cells. Prostate 1990; 17: 13-8.
42. Costello LC, Franklin RB. Effect of prolactin on the prostate. Prostate 1994; 24:162-8.
43. Yarilin AA. Foundations of Immunology. Moscow: Medicine,1999.
44. Roitt I, Brostoff J, Male D. Immunology. Moscow: Mir, 2000.
2. Bremner WJ, Vitietto MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. Clin Endocrin Metab 1983; 56:1278-81.
3. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex-hormone levels in middle-aged men: Results of the Massachusetts male aging study. Clin Endocrinol 1991; 73:1016-25.
4. Vermeulen A, Kaufman JM. Androgens and cardiovascular disease in men and women. The Aging Male 1998; 1:35-50.
5. Pechersky AV, Semiglazov VF, Mazurov VI, Karpischenko Al, Mikhailichenko VV, Udintsev AV, Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, estradiol and prostate volume. Intern J Androl 2002; 25: 119-25.
6. Pechersky AV, Semiglazov VF, Loran OB, et al. Changes in the level of cytokines among patients with prostate cancer after orchiectomy. Terra Medica, in its special thematic edition "Laboratory Diagnostics" 2003; 2: 26-30.
7. Bershtein LM. Hormonal carcinogenesis. St. Petersburg: Nauka, 2000.
8. Fernandez E, La Vecchia C, D'Avanzo B, Franceschi S, Parazinni F, Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer. Br J Cancer 1996;73:1431-5.
9. Lopatkin NA. Guide to urology. Moscow: Medicine, 1998: 3.
10. Lavin N. Endocrinology. Moscow: Practica,1999.
11. Loran OB, SegakI AS, Supryaga OM. Andriol in the treatment secretion infertility and climacteric syndrome in men. Urol Nephrol 1999; 3: 41-4.
12. Morales A, Bain J, Ruijs A. et al. Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Intern J Impot Res 1996;8:95-7.
13. Jonat W, Maass H, Stegner HE. Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res 1986; 46: 4296-8.
14. Glantz SA. Primer of biostatistics. Moscow: Practica, 1999.
15. Kettyle WM, Arky RA. Endocrine pathophysiology. Moscow: Binom Publishers, 2001.
16. Farber E. Cell proliferation as a major risk factor for cancer: a concept of doubtful validity. Cancer Res 1995; 55: 3759-62.
17. Sporn MB. The war on cancer. Lancet 1996; 347: 1377-81.
18. Russo J, Russo IH. Differentiation and breast cancer. Medicina (B. Aires) 1997; 57:81-91.
19. Vasilyev Yu. M. Social behavior of normal cells and antisocial behavior of tumorous cells. Soros Educational J 1997; 4:17-22.
20. Burrows H, Horning E. Oestrogens and neoplasia. Springfield, Illinois: Charles C. Thomas Publ, 1952. p. 189.
21. Zazerov VG, Severin ES. Molecular mechanisms of oncogenesis of the prostate. Vestnik of the Russian Academy of Medical Sciences 1998; 5: 29-35.
22. Neveu PJ, Le Moal M. Physiological basis for neuroimmunomodulation. Fundam Clin Pharmacol 1990;4: 281-305.
23. Besedovsky HO, Del Rey A. Immune-neuroendocrine interactions: facts and hypotheses. Endocrine Rev 1996;17:64-102.
24. Bershtein LM. Extragonadal Estrogen Production (role in physiology and pathology). St. Petersburg: Nauka, 1998.
25. Borkovwski A, Dosogne M, Declerq P, Muquardt C, Machin D. Estrogen oestradiol conversion by blood mononuclear cells in normal subjects and in patients with mammary and non-mammary carcinomas. Cancer Res 1978; 38: 2174-9.
26. Milewich L, Whisenant MG, Sawyer MK. Androstenedione metabolism by human lymphocytes. J Steroid Biochem 1982; 16:81-5.
27. Coddington CC, Letterie GS, Klein TA, Winkee CA. Androgen metabolism by human peritoneal macrophages. Steroids 1988;51:143-61.
28. Frisch RE, Canick JA, Tulchinsky D. Human fatty marrow aromatizes androgen to estrogen. J Clin Endocrinol Metabol 1980;51:394-6.
29. Lea CK, Ebrahim H, Tennant S, Flanagan AM. Aromatase cytochrome P450 transcripts are detected in fractured human bone but not in normal skeletal tissue, Bone 1997;21:433-40.
30. Mor G, Yue W, Santen RJ, et al. Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem and Mol Biol 1998;67: 403-11.
31. Weigent DA, Blalock JE. Interaction between neuroendocrine and immune systems: common hormones and receptors. Immunol Rev 1987; 100: 79-108.
32. Korneva EA, Shkhinek EK. Hormones and the Immune System. Leningrad: Nauka, 1988,
33. Pankov A. Yu. Prolactin. Large Medical Encyclopedia. Moscow: Sovetskaya Aencyclopedya, 1983; 21: 134.
34. Lueprasitsakul P, Longcope C. Aromatase activity of human adipose tissue stromal cells: effects of thyroid hormones and progestogens. Proc Soc Exp Biol and Med 1990; 194:337-41.
35. Jakob F, Homann D, Seufert J, Schneider D, Kohrle J. Expression and regulation of aromatase cytochrome P450 in THP1 human myeloid leukemia cells. Molec and Cell Endocrinol 1995; 110: 27-33.
36. Shozu M, Takayama K, Zhao Y, Simpson ER. Hormonally controlled alternative promoters regulate aromatase expression in human THP-1 cells. Proc 4th Intern Aromatase Conf. Tahoe City, California, 1996: A-15.
37. Mendelson CR, Simpson ER. Regulation of estrogen biosynthesis by human adipose cells in vitro. Molec and Cell Endocrinol 1987; 52: 169-76.
38. Ryde CM, Nicholls JE, Dowsett M. Steroid and growth factor modulation of aromatase activity in MCF7 and T 47D breast carcinoma cell lines. Cancer Res 1992;52: 1411-5.
39. Naz RK. Prostate: basic and clinical aspects. New York: CRC Press, 1997. p. 337.
40. Tareeva IE. Nephrology. Moscow: Medicine, 1995;1.
41. Franklin RB, Costello LC. Prolactin directly stimulates citrate production and mitochondrial aspartate aminotransferase of prostate epithelial cells. Prostate 1990; 17: 13-8.
42. Costello LC, Franklin RB. Effect of prolactin on the prostate. Prostate 1994; 24:162-8.
43. Yarilin AA. Foundations of Immunology. Moscow: Medicine,1999.
44. Roitt I, Brostoff J, Male D. Immunology. Moscow: Mir, 2000.
Downloads
Published
2006-06-30
How to Cite
1.
Pechersky AV, Semiglazov VF, Komyakov BK, Guliev BG, Gorelov AI, Novikov AI, Pechersky VI, Simonov NN, Gulyaev AV, Samusenko IA, Vonsky MS, Mittenberg AG, Loran OB. Increase of the Expression of Receptors of Steroid Hormones in Patients with a Partial Androgen Deficiency of Aging Men (PADAM). Thai J Surg [Internet]. 2006 Jun. 30 [cited 2024 Dec. 23];27(2):93-100. Available from: https://he02.tci-thaijo.org/index.php/ThaiJSurg/article/view/242039
Issue
Section
Original Articles
License
Articles must be contributed solely to The Thai Journal of Surgery and when published become the property of the Royal College of Surgeons of Thailand. The Royal College of Surgeons of Thailand reserves copyright on all published materials and such materials may not be reproduced in any form without the written permission.
